Equity in Sight: Addressing Disparities with Advanced Treatment Approaches

Jennifer, I. Lim, MD, FASRS, FARVO, Program Chair
Marion H. Schenk Chair in Ophthalmology
Vice-Chair for Diversity, Equity & Inclusion
Director of the Retina Service
UIC Distinguished 
Professor of Ophthalmology
University of Illinois at Chicago
Chicago, IL

Jeremiah Brown Jr, MD, MS, FASRS
Retina Consultants of Texas
San Antonio, TX

Rahul N. Khurana, MD, FASRS
Partner, Northern California 
Retina Vitreous Associates
Clinical Associate Professor of Ophthalmology
University of California 
San Francisco Medical Center
San Francisco, CA

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.

The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

Jeremiah Brown Jr, MD, MS, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Common Stock: Regeneron. Consultant: 4DMT, Apellis Pharmaceuticals, Genentech, and Outlook Therapeutics. Grant/Research Support: Annexon, Apellis Pharmaceuticals, Eyebio, EyePoint Pharmaceuticals, Genentech, Kodiak Sciences, Opthea, Outlook Therapeutics, and Regenxbio. Speaker’s Bureau: Apellis Pharmaceuticals, Astellas, and Genentech.  

Rahul N. Khurana, MD, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Clearside, Genentech/Roche, and Regeneron. Grant/Research Support: Annexion, Apellis Pharmaceuticals, Clearside Biomedical, Opthea, Regenxbio, and Roche.

Jennifer, I. Lim, MD, FASRS, FARVO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Astellas/Iveric, Aura, Cognition, EyePoint Pharmaceuticals, Eyenuk, Genentech/Roche, Luxa, Opthea, Regeneron, Unity, and Viridian. Advisory Board: Alcon, Alimera, Apellis Pharmaceuticals, Bausch + Lomb, and Ocular Therapeutix. Grant/Research Support: Aldeyra, Genentech/Roche, Graybug, Janssen/Johnson & Johnson, Kyoto Drug/Discovery, NGM, Ocular Therapeutix, Regeneron, Regenxbio, Spring Vision, and Stealth.

The Evolve and staff, planners, reviewer, and writers have no financial relationships with ineligible companies.